GlassScriptPhysician profile
Catherine M Westerband
NPI 1942218078
$4,081.56
in general payments reported to CMS, 2019-2025
29 companies · $570 in 2025
The $570 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $454 · 2021: $736 · 2022: $499 · 2023: $806 · 2024: $628 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.45 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $858.13 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Organon LLC | $414.02 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $376.73 | 2019-2025 | Gardasil 9, Gardasil |
| Myovant Sciences INC. | $254.11 | 2021-2022 | |
| Hologic Sales and Service, LLC | $246.31 | 2022-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $197.76 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $197.25 | 2023-2025 | Myfembree |
| Pfizer INC. | $179.50 | 2019-2025 | |
| Biogen, INC. | $178.40 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $145.25 | 2019-2025 | Paragard T 380a, Summit Doppler |
| Exeltis, USA INC. | $141.40 | 2020-2025 | Slynd |
| Therapeuticsmd, INC. | $138.50 | 2019-2021 | |
| Avion Pharmaceuticals | $136.45 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.24 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $100.94 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $65.05 | 2020-2021 | |
| Millicent US INC | $48.17 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Myriad Women'S Health, INC. | $47.75 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $47.51 | 2021 | |
| Becton, Dickinson and Company | $43.22 | 2024 | Arista Ah Flexitip |
| Medtronic, INC. | $27.21 | 2024 | Ligasure |
| Smith+Nephew, INC. | $21.67 | 2025 | Pico 14, Pico 7 |
| Vertical Pharmaceuticals, LLC | $17.78 | 2019 | |
| Convatec INC. | $17.66 | 2021 | |
| Boston Scientific Corporation | $15.66 | 2024 | Solyx Sis System |
| Lupin INC. | $12.74 | 2019 | |
| Allergan, INC. | $11.75 | 2020 | |
| Aspira Women'S Health INC | $10.40 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Westerband listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.